Boticarium II

  1. Medrano Albéniz, Juan
Revista:
Revista de la Asociación Española de Neuropsiquiatría

ISSN: 0211-5735

Año de publicación: 2012

Volumen: 32

Número: 113

Páginas: 133-146

Tipo: Artículo

DOI: 10.4321/S0211-57352012000100013 DIALNET GOOGLE SCHOLAR lock_openAcceso abierto editor

Otras publicaciones en: Revista de la Asociación Española de Neuropsiquiatría

Resumen

Aviso a los navegantes: Este resumen de novedades en Psicofarmacolog?a se construye en base a dos premisas. La primera es que sus fuentes, en la medida de lo posible, sean abiertas y por lo tanto puedan ser consultadas por cualquier lector interesado en ellas. La segunda es que lo recogido se oriente al uso clínico de los psicofármacos, sin detenerse en hallazgos relacionados con la efectividad de los medicamentos (que habitualmente suelen tener mecanismos de promoción más certeros y eficaces) Por este motivo, sus contenidos pueden resultar sombríos, preocupantes o incluso pueden aparentar una disposición contraria al uso de psicofármacos. No es ni mucho menos esta la intención del recopilador, gran parte de cuya actividad asistencial gira en torno a la prescripción de medicamentos. Más bien, la vocación de esta sección es transmitir información que fomente el uso racional, prudente y sanamente escéptico de los fárrmacos psiquiátricos. Nada menos...

Referencias bibliográficas

  • (1) Stip E, Abdel-Baki A, Bloom D, Grignon S, Roy M-A. Les antipsychotiques injectables à action prolongée: avis d’experts de l’Association des médecins pychiatres du Québec. Rev Can Psychiatrie / Can J Psychiatry 2011; 56: 367–76 [Accesible en: http://publications.cpa-apc.org/media. php?mid=1180].
  • (2) Shajahan P, Spence E, Taylor M, Daniel D, Pelosi P. Comparison of the effectiveness of depot antipsychotics in routine clinical practice. The Psychiatrist 2010; 34: 273-279 [Accesible en: http://pb.rcpsych.org/content/34/7/273].
  • (3) Saphris (asenapine maleate): Drug Safety Communication: Serious Allergic Reactions [Posted 09/01/2011] [Accesible en: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm270600.htm].
  • (4) Sycrest 5 mg. Ficha técnica o resumen de las características del producto [Accesible en: http://www.ema.europa.eu/docs/ es_ES/document_library/EPAR_-_Product_Information/human/001177/WC500096895.pdf].
  • (5) Lambert T. Managing the metabolic adverse effects of antipsychotic drugs in patients with psychosis. Australian Prescriber 2011; 34: 97-9 [Accesible en: http://www.australianprescriber.com/upload/pdf/issues/159.pdf].
  • (6) García Gil M. Monitorizando antipsicóticos. Hemos Leído… 12 septiembre 2011 [Accesible en: http://www.hemosleido.es/?p=916]
  • (7) Nielsen J, Skadhede S, Correll CU. Antipsychotics Associated with the Development of Type 2 Diabetes in Antipsychotic-Naı¨ve Schizophrenia Patients. Neuropsychopharmacology 2010; 35: 1997–2004 [Accesible en: http:// www.nature.com/npp/journal/v35/n9/pdf/npp201078a.pdf].
  • (8) Wolfe J. Antipsychotics Increasingly Prescribed for Anxiety. Psychiatric News 2011; 46 (17): 20-27 [Accesible en: http://psychnews.psychiatryonline.org/newsArticle.aspx?articleid=116608].
  • (9) Levin A. Concern Raised Over Antipsychotic’s Use for Sleep Problems. Psychiatric News 2011; 46( 17): 21 [Accesible en: http://psychnews.psychiatryonline.org/newsArticle.aspx?articleid=116611].
  • (10) Caroff SN, Miller DD, Dhopesh V, Campbell E. Is there a rational management strategy for tardive dyskinesia?. Current Psychiatry 2011; 10(10): 22-32 [Accesible en: http://www.currentpsychiatry.com/article_pages.asp?aid=9947]
  • (11) AEMPS. Antipsicóticos: riesgo de efectos extrapiramidales y síntomas de retirada en recién nacidos tras exposición durante el embarazo. En Informe Mensual Julio2011 Medicamentos de uso humano [Accesible en: http://www.aemps.gob.es/informa/informeMensual/2011/julio/informemedicamentos.htm].
  • (12) Food and Drug Administration. Antipsychotic drugs: Class Labeling Change-Treatment During Pregnancy and Potential Risk to Newborns; 02/22/2011 [Accesible en: http://www.fda.gov/Safety/MedWatch/ SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm244175.htm].
  • (13) Sinclair L. Antipsychotic Labels to Cite Risks to Newborns. Psychiatric News 2011; 46 (7): 12 [Accesible en: http://pn.psychiatryonline.org/content/46/7/12.1.full].
  • (14) Food and Drug Administration. Seroquel (quetiapine fumarate) Tablets, Seroquel (quetiapine fumarate) XR. Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – July 2011 [Accesible en: http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm267700.htm].
  • (15) Seroquel: Full prescribing information [Accesible en: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020639s049s054lbl.pdf].
  • (16) Bernardo M, Vieta E, Saiz Ruiz J, Rico-Villademoros F, Álamo C, Bobes J y Grupo RECAP. Recomendaciones para el cambio de antipsicóticos. Posicionamiento de la Sociedad Española de Psiquiatría y Sociedad Española de Psiquiatría Biológica. Rev Psiquiatr Salud Ment (Barc) 2011; 4: 150-68 [Accesible en: http://apps.elsevier.es/watermark/ctl_servlet?f=10&pident_articulo=90027950&pident_usuario=0&pcontactid=&pident_revista=286&ty=41&accion=L&origen=elsevier&web =www.elsevier.es&lan=es&fichero=286v04 n03a90027950pdf001.pdf].
  • (17) Chopra A, Rai A, Philbrick K, Das P. A dangerous GI complication. Current Psychiatry 2011 (7): 68-72 [Accesible en: http://www.currentpsychiatry.com/pdf/1007/1007CP_Cases.pdf].
  • (18) Fulde G, Preisz P. Managing aggressive and violent patients. Australian Prescriber 2011; 34 (4): 116-118 [Accesible en: http://www.australianprescriber.com/upload/pdf/articles/1208.pdf].
  • (19) Kapur S, Zipursky R, Remington G, Jones C, McKay G, Houle S. PET evidence that loxapine is an equipotent blocker of 5-HT2 and D2 receptors: implications for the therapeutics of schizophrenia. Am J Psychiatry 1997; 154: 1525-9 [Abstract en: http://www.ncbi.nlm.nih.gov/pubmed/9356559].
  • (20) Geller JL, Gaulin BD, Barreira PJ. A practitioner’s guide to use of psychotropic medication in liquid form. Hosp Comm Psychiatry 1992; 43: 963-71.
  • (21) Allen MH, Feifel D, Lesem MD, Zimbroff DL, Ross R, Munzar P, et al.Efficacy and safety of loxapine for inhalation in the treatment of agitation in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2011; 72: 1313-21 [Abstract: http://www.ncbi.nlm.nih.gov/pubmed/21294997].
  • (22) Eyding D, Lelgemann M, Grouven U, Härter M, Kromp M, Kaiser T, et al. Reboxetine for acute treatment of major depression: systematic review and metaanalysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. BMJ 2010;341:bmj.c4737[Accesible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2954275/pdf/bmj.c4737.pdf].
  • (23) Medicines and Healthcare Products Regulatory Agency. Safety warnings and messages for medicines. Reboxetine: A review of the benefits and risks. 14 September 2011 [Accesible en: http://www.mhra.gov.uk/home/groups/pl-/documents/websiteresources/con129107.pdf].
  • (24) Medicines and Healthcare Products Regulatory Agency. Drug Safety Update. Reboxetine: benefit-risk balance reviewed. September 2011 [Accesible en: http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON128957].
  • (25) Food and Drug Administration. Celexa (citalopram hydrobromide): Drug Safety Communication - Abnormal Heart Rhythms Associated With High Doses [Posted 08/24/2011] [Accesible en: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm269481.htm]
  • (26) Agencia Española de Medicamentos y Productos Sanitarios. Citalopram y prolongación del intervalo QT del electrocardiograma. Fecha de publicación: 27 de octubre de 2011 [Accesible en: http://www.aemps.gob.es/informa/notasInformativas/medicamentosUsoHumano/seguridad/2011/NI-MUH_19-2011.htm].
  • (28) Croen LA, Grether JK, Yoshida CK, Odouli R, Hendrick V. Antidepressant Use During Pregnancy and Childhood Autism Spectrum Disorders. Arch Gen Psychiatry 2011; 68: 1104-12 [Abstract en: http://archpsyc.ama-assn.org/cgi/content/short/ archgenpsychiatry.2011.73].
  • (29) Sinclair S. Weak Association Found Between ASD, SSRI Use in Pregnancy. Psychiatric News 2011;46 (15):1-26 [Accesible en: http://psychnews.psychiatryonline.org/newsArticle.aspx?articleid=115871].
  • (30) Coupland C, Dhiman P, Morriss R, Arthur A, Barton G, Hippisley-Cox J. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ 2011;343:bmj.d4551 [Accesible en: http://www.bmj.com/content/343/bmj. d4551.full].
  • (31) Medicines Safety Update 2011; 2 (4) [Accesible en: http://www.australianprescriber.com/magazine/34/4/108/11].
  • (32) Food and Drug Administration. Cymbalta (duloxetine hydrochloride). Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER). September 2011 [Accesible en: http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm255064.htm].
  • (33) Food and Drug Administration. Zoloft (sertraline hydrochloride) Tablets and Oral Concentrate. Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – August 2011 [Accesible en: http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm271273.htm].
  • (34) Lyoo IK, Dager SR, Kim JE, Yoon SJ, Friedman SD, Dunner DL, et al. Lithium-Induced Gray Matter Volume Increase As a Neural Correlate of Treatment Response in Bipolar Disorder: A Longitudinal Brain Imaging Study. Neuropsychopharmacology 2010; 35: 1743–1750 [Accesible en: http://www.nature.com/npp/journal/v35/n8/full/npp201041a.html].
  • (35) Food and Drug Administration. Valproate Products: Drug Safety Communication - Risk of Impaired Cognitive Development in Children Exposed In Utero (During Pregnancy). Including valproate sodium (Depacon), divalproex sodium (Depakote, Depakote CP, and Depakote ER), valproic acid (Depakene and Stavzor), and their generics [Posted 06/30/2011] [Accesible en: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm261610.htm].
  • (36) AEMPS. Medicamentos de uso humano, octubre 2011 [Accesible en: http://www.aemps.gob.es/informa/ informeMensual/2011/octubre/informe-medicamentos.htm].
  • (37) Jain S, Beste B. Valproateinduced hair loss: What to tell patients. Current Psychiatry; 2011 (11): 74 [Accesible en: http://www.currentpsychiatry.com/pdf/1011/1011CP_PRLS_Jain.pdf].
  • (38) Becerra-García JA. Efectos cognitivos del consumo prolongado de alprazolam: el síndrome amnésico. Trastor Adictivos 2011; 13: 80-3 [Accesible en: http://www.elsevier.es/es/revistas/trastornos-adictivos-182/efectoscognitivos-consumo-prolongado-alprazolam-sindrome-amnesico-90038153-casoclinico-2011?utm_source=Newsletter&utm_medium=email&utm_campaign=Trastornos +Adictivos%3A+Nuevo+Sumario+Vol.13+N%C3%BAm.02].
  • (39) Food and Drug Administration. Xanax (alprazolam) and Xanax XR. Detailed View: Safety Labeling Changes ApproJ. Medrano ved By FDA Center for Drug Evaluation and Research (CDER) – August 2011 [Accesible en: http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm271398.htm].
  • (40) Food and Drug Administration. Lyrica (pregabalin) capsules and oral solution. Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – June 2011and August 2011 [Accesible en: http://www. fda.gov/Safety/MedWatch/SafetyInformation/ucm262247.htm].
  • (41) Food and Drug Administration. Neurontin (gabapentin) Capsules, Tablets, and Oral Solution. Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) - April 2009 and August 2011 [Accesible en: http://www.fda.gov/Safety/MedWatch/SafetyInformation/Safety-RelatedDrugLabelingChanges/ucm154552.htm].
  • (42) Pierce AM, Brahm NC. Opiates and psychotropics: Pharmacokinetics for practitioners. Current Psychiatry 2011 (6): 83-6 [Accesible en: http://www.currentpsychiatry.com/pdf/1006/1006CP_Savvy.pdf].
  • (43) Labos C, Dasgupta K, Nedjar H, Turecki G, Rahme E. Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction. CMAJ 2011; 183: 1835-43 [Accesible en: http://www.cmaj.ca/content/183/16/1835. full.pdf+html].
  • (44) Food and Drug Administration. Zyvox (linezolid): Drug Safety Communication - Serious CNS Reactions Possible When Given to Patients Taking Certain Psychiatric Medications [Posted 07/26/2011 [Accesible en: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm265479.htm].
  • (45) Food and Drug Administration. Orap (pimozide) 1 mg and 2 mg tablets. Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER). September 2011 [Accesible en: http://www.fda.gov/Safety/ MedWatch/SafetyInformation/ucm175823.htm].
  • (46) Orap. Ficha técnica o resumen de las características del producto. [Accesible en: https://sinaem4.agemed.es/consaem/ especialidad.do?metodo=verFichaWordPdf&codigo=49504&formato=pdf&formulario=FICHAS].
  • (47) Food and Drug Administration. Zyban (bupropion hydrochloride) SustainedRelease tablets. Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)- July 2009 and August 2011 [Accesible en: http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm176815.htm].
  • (48) Singh S, Loke YK, Spangler JG, Furberg CD. Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. CMAJ 2011; 183: 1359-66 [Accesible en: http://www.cmaj.ca/content/183/12/1359.full.pdf+html].
  • (49) Food and Drug Administration. Chantix (varenicline): Label Change - Risk of Certain Cardiovascular Adverse Events [UPDATED 07/22/2011] [Disponible en: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm259469.htm].
  • (50) Méndez R. Dudas sobre el fármaco de Pfizer para dejar de fumar. El País, 05 de Julio de 2011 [Accesible en http://www.elpais.com/articulo/sociedad/Dudas/farmaco/Pfizer/dejar/fumar/elpepisoc/20110705elpepisoc_10/Tes].
  • (51) Agencia Española de Medicamentos y Productos Sanitarios. Vareniclina (Champix®): Evaluación de un nuevo análisis sobre reacciones cardiovasculares. 22 de julio de 2011 [Accesible en: http://www.aemps.gob.es/informa/notasInformativas/medicamentosUsoHumano/seguridad/2011/NI-MUH_15-2011.htm].
  • (52) Moore TJ, Furberg CD, Glenmullen J, Maltsberger JT, Singh S (2011) Suicidal Behavior and Depression in Smoking Cessation Treatments. PLoS ONE 6(11):e27016. doi:10.1371/journal.pone.0027016 [Accesible en: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0027016].
  • (53) BOE, 20 de agosto de 2011. Accesible en: http://www.boe.es/boe/dias/2011/08/20/pdfs/BOE-A-2011-14021.pdf
  • (54) Fonseca L. Los psiquiatras cargan contra los genéricos. El Comercio, 9 denoviembre de 2011 [Accesible en http://www.elcomercio.es/v/20111109/asturias/psiquiatras-cargan-contra-genericos-20111109.html].
  • (55) De Benito E. Los médicos pueden recetar desde hoy por marca si esta es la más barata. El País, 1 de noviembre de 2011 [Accesible en: http://www.elpais.com/articulo/sociedad/medicos/pueden/recetar/hoy/marca/barata/elpepusoc/20111027elpepusoc_10/Tes].
  • (56) MFV. La receta de génericos se aplica ya en las consultas médicas de Osakidetza. EL Correo, 2 de noviembre de 2011 [Accesible en: http://www.elcorreo.com/vizcaya/prensa/20111102/pvasco-espana/receta-genericos-aplica-consultas-20111102.html]
  • (57) Albersheim SG, Golan A. The Physician’s Relationship with the Pharmaceutical Industry: Caveat Emptor...Buyer Beware! IMAJ 2011; 13: 389–393 [Accesible en: http://www.ima.org.il/imaj/ar11jul-01.pdf].
  • (58) Herreros Ortega A. ¿Cuánto nos costará ahorrar 2.000 millones? El Médico Interactivo, noviembre de 2011 [Accesible en: http://www.elmedicointeractivo.com/analisis/tribuna/107003/cuanto-nos-costara-ahorrar-2000-millones]
Fuente de los datos: Dialnet